Contact this trialFirst, we need to learn more about you.
BI 764198 for Focal Segmental Glomerulosclerosis
Recruiting0 awardsPhase 2
Oak Brook, Illinois
This trial is testing a new medication to see if it can improve kidney function in patients with primary focal segmental glomerulosclerosis (FSGS). Participants will be randomly assigned to one of four groups, three of which will receive different doses of the medication and one of which will receive a placebo. The trial will last for four months, during which participants will take the medication or placebo once daily. Kidney function will be monitored via urine samples, and general health will be monitored via regular checkups.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.